AR011607A1 - Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar - Google Patents

Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar

Info

Publication number
AR011607A1
AR011607A1 ARP980100442A ARP980100442A AR011607A1 AR 011607 A1 AR011607 A1 AR 011607A1 AR P980100442 A ARP980100442 A AR P980100442A AR P980100442 A ARP980100442 A AR P980100442A AR 011607 A1 AR011607 A1 AR 011607A1
Authority
AR
Argentina
Prior art keywords
cancer
tumor suppressor
gene
tumor
isolated
Prior art date
Application number
ARP980100442A
Other languages
English (en)
Spanish (es)
Original Assignee
Univ Texas
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25152739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011607(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas, Myriad Genetics Inc filed Critical Univ Texas
Publication of AR011607A1 publication Critical patent/AR011607A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ARP980100442A 1997-01-30 1998-01-30 Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar AR011607A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/791,115 US6262242B1 (en) 1997-01-30 1997-01-30 Tumor suppressor designated TS10Q23.3

Publications (1)

Publication Number Publication Date
AR011607A1 true AR011607A1 (es) 2000-08-30

Family

ID=25152739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100442A AR011607A1 (es) 1997-01-30 1998-01-30 Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar

Country Status (14)

Country Link
US (1) US6262242B1 (cg-RX-API-DMAC7.html)
EP (2) EP0972024B2 (cg-RX-API-DMAC7.html)
JP (5) JP2001511002A (cg-RX-API-DMAC7.html)
AR (1) AR011607A1 (cg-RX-API-DMAC7.html)
AT (1) ATE499444T1 (cg-RX-API-DMAC7.html)
AU (1) AU745296B2 (cg-RX-API-DMAC7.html)
CA (1) CA2278849C (cg-RX-API-DMAC7.html)
DE (1) DE69842141D1 (cg-RX-API-DMAC7.html)
DK (1) DK0972024T4 (cg-RX-API-DMAC7.html)
ES (1) ES2361044T5 (cg-RX-API-DMAC7.html)
IL (1) IL131168A0 (cg-RX-API-DMAC7.html)
PT (1) PT972024E (cg-RX-API-DMAC7.html)
WO (1) WO1998033907A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA98756B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
WO1998034624A1 (en) * 1997-02-07 1998-08-13 The Trustees Of Columbia University In The City Of New York Use of the p-ten suppressor gene in diagnosis and treatment of cancer
US6225120B1 (en) 1997-05-15 2001-05-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
EP1012338B1 (en) * 1997-08-26 2005-06-15 The Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
AU2002359697A1 (en) * 2001-12-20 2003-07-09 Tularik Inc. Identification of an amplified gene and target for drug intervention
EP1756137A4 (en) * 2003-11-05 2007-10-31 Univ Texas DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
AU2011305445B2 (en) 2010-09-24 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Direct capture, amplification and sequencing of target DNA using immobilized primers
BR122015032159A2 (pt) 2011-12-30 2019-08-27 Abbott Molecular Inc. método para detectar câncer de próstata utilizando conjunto de sondas compreendendo sondas lócus específicas para myc e para homólogo de fosfatase e tensina (pten) e sondas centroméricas para cromossomos 7, 8 e 10, bem como conjunto de sondas e kit

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
FR2616841A1 (fr) 1987-06-17 1988-12-23 Rauner Hans Perfectionnements au systeme de bloquage en position ouverte a levier de serrage pivotant, pour fiches et paumelles de portes et de fenetres
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
JP2000500329A (ja) 1995-10-23 2000-01-18 インペリアル キャンサー リサーチ テクノロジィ リミテッド 癌罹病性の診断およびその治療
EP1012338B1 (en) * 1997-08-26 2005-06-15 The Board Of Regents, The University Of Texas System A tumor suppressor designated ts10q23.3
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
WO1998033907A1 (en) 1998-08-06
ES2361044T5 (es) 2014-10-01
JP2010259438A (ja) 2010-11-18
JP4768783B2 (ja) 2011-09-07
CA2278849C (en) 2016-04-19
EP0972024B1 (en) 2011-02-23
AU6018998A (en) 1998-08-25
CA2278849A1 (en) 1998-08-06
ES2361044T3 (es) 2011-06-13
DK0972024T4 (da) 2014-07-07
AU745296B2 (en) 2002-03-21
ATE499444T1 (de) 2011-03-15
EP0972024A1 (en) 2000-01-19
US6262242B1 (en) 2001-07-17
ZA98756B (en) 1998-08-25
DK0972024T3 (da) 2011-04-26
DE69842141D1 (de) 2011-04-07
JP5202583B2 (ja) 2013-06-05
EP2366712A2 (en) 2011-09-21
EP2366712A3 (en) 2012-11-14
JP2014155493A (ja) 2014-08-28
JP2013128485A (ja) 2013-07-04
JP2001511002A (ja) 2001-08-07
JP2009039107A (ja) 2009-02-26
PT972024E (pt) 2011-05-05
IL131168A0 (en) 2001-01-28
EP0972024B2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
Park et al. Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis
Holaska et al. An emerin ‘proteome’: purification of distinct emerin-containing complexes from HeLa cells suggests molecular basis for diverse roles including gene regulation, mRNA splicing, signaling, mechano-sensing and nuclear architecture
Sethi et al. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues
Soteriou et al. A survey of interactions made by the giant protein titin
van Kuijk et al. Human and murine fibroblast single-cell transcriptomics reveals fibroblast clusters are differentially affected by ageing and serum cholesterol
Hoek et al. hnRNP A2 selectively binds the cytoplasmic transport sequence of myelin basic protein mRNA
McMahon et al. Human α spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex
Eguchi et al. Intracellular MMP3 promotes HSP gene expression in collaboration with chromobox proteins
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
Li Mow Chee et al. Mena regulates nesprin-2 to control actin–nuclear lamina associations, trans-nuclear membrane signalling and gene expression
Hayez et al. High TMEM 45A expression is correlated to epidermal keratinization
EA199700447A1 (ru) Последовательность днк и кодируемый ею специфический для молочной железы белок карциномы молочной железы
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
Sakai et al. Novel RUNX1‐PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t (1; 21)(p36; q22)
Schneider et al. Evidence that vitronectin is a potent migration-enhancing factor for cancer cells chaperoned by fibrinogen: a novel view of the metastasis of cancer cells to low-fibrinogen lymphatics and body cavities
Lee et al. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL
Yoon et al. NOTUM is involved in the progression of colorectal cancer
Kolovskaya et al. DNA-aptamer/protein interaction as a cause of apoptosis and arrest of proliferation in Ehrlich ascites adenocarcinoma cells
Myers et al. Type XIX collagen purified from human umbilical cord is characterized by multiple sharp kinks delineating collagenous subdomains and by intermolecular aggregates via globular, disulfide-linked, and heparin-binding amino termini
Deng et al. Expression of immunoglobulin A in human mesangial cells and its effects on cell apoptosis and adhesion
Goldstein et al. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries
Wang et al. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma
EP2366712A3 (en) A tumor suppressor designated TS10Q23.3
Vegliante et al. NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma
Li et al. EPLIN-β is a novel substrate of ornithine decarboxylase antizyme 1 and mediates cellular migration

Legal Events

Date Code Title Description
FA Abandonment or withdrawal